RE:logic would somewhat dictatedavewho wrote: if they moved the r/s timeline up then the timeline for rev growth and Aristotle could also be moving faster than originally thought.
But sometimes the market and management moves aren't always logical. I've seen my share of bad r/s's
The BOD, management and the new institutional investors must have agreed now is the time. Hope they are right.
TMX still shows an active listing so not likely for that reason and no other filings I can see.
TD now shows EPS 0.01 and a low p/e of 9.5 which works out to earnings of about $4m. They don't need any money. The eps should jump to .08 after the r/s?
Aristotle is the future player here, yet we are all speculating on its completion timeline - we have read corporate statements indicating end of 2020 or Q1 for roll out, yet we don't have the full picture of its current status - yes it may be moving faster than originally thought, but in this hospital COVID environment it could also be moving slower - point is we don't really know. NOW is the time for an NR to investors outlining its actual progress - this would include specific # of clinical trials completed and most importantly how many more are required for certification. This is the only way we will have the full picture. The timing of this R/S should be supported with facts that are reassuring vis a vis Aristotle.